Factbox: Drugs to watch at Roche, Sanofi and GSK

Reuters

(Reuters) - GlaxoSmithKline, Roche and Sanofi all hold investor days this week. Below are three new drugs to watch from each company, with consensus annual sales in 2020, according to Thomson Reuters Cortellis. *GlaxoSmithKline: - Nucala, severe asthma injection, $756 million - Shingrix, shingles vaccines, $594 million - sirukumab, rheumatoid arthritis (with J&J), $980 million *Roche - ocrelizumab, multiple sclerosis, $1,051 million - atezolizumab, cancer, $3,188 million - ACE-910, haemophilia, $721 million *Sanofi: - dupilumab, asthma/dermatitis (with Regeneron), $1,409 million - sarilumab, rheumatoid arthritis (with Regeneron), $516 million - LixiLan, diabetes, $815 million (Reporting by Ben Hirschler. Editing by Jane Merriman)